Clinical trials: Recurrent Thromboembolic Disease
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Venous Thrombosis, Pulmonary Embolism
Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep…
- Trial name
- Du Lac (NCT01164540)
- Testing
- Rosuvastatin (AZD4522)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT)
Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study
This study is a prospective, multicenter international trial aimed at assessing the actual incidence, identifying associated factors, and evaluating the clinical consequences of both persistent and recurrent device-related…
- Conditions
- Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT), Thromboembolic Event, Major Cardioembolic Events
- Trial name
- RE-DRT (NCT06177704)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Pulmonary Embolism, Proximal Deep Vein Thrombosis
Six Years of Follow-up After Idiopathic Venous Throbmoembolism
Beyond the first 6 months of anticoagulation, patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after stopping anticoagulations.
- Trial name
- Padis-Ext (NCT02884934)
- Where
- 10 sites in France
- Volunteers
- 409 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome
Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years. Reduce the risk of recurrence is a serious public health issue.
- Trial name
- NCT02904967
- Testing
- Extra Blood Draw
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cardiovascular Diseases, Thromboembolism
Risk Factors for Venous Thromboembolism in the Community
To evaluate the trends in the incidence of venous thromboembolism, to determine the risk factors for venous thromboembolism in patients with medical and surgical illness, and to evaluate the efficacy of the anticoagulant therapy…
- Trial name
- NCT00011180
- Where
- United States
- Volunteers
- 385 people
- Sponsor
- Mayo Clinic
Venous Thromboembolism
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
- Trial name
- DaPaR (NCT05536791)
- Testing
- Dabigatran Etexilate (DE)
- Where
- 6 sites in Germany, Netherlands and 2 more
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Venous Thromboembolism
Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)
Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk.
- Trial name
- PRONOSPECT (NCT06372730)
- Testing
- Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)
- Where
- 13 sites in France
- Volunteers
- 665 people
- Sponsor
- University Hospital, Brest
Breast Cancer, Colorectal Cancer
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
RATIONALE: Chemotherapy may cause blood clots to form in the thigh, leg, and lung. This study may help doctors understand how often blood clots occur in patients undergoing chemotherapy.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00433602
- Testing
- clinical observation, management of therapy complications, ultrasound imaging
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Deep Vein Thrombosis, Pulmonary Embolism
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
The purpose of this study is to determine if the risk of recurrent venous thromboembolism (VTE) after stopping therapy is low and acceptable in patients with a first unprovoked proximal deep vein thrombosis (DVT) or pulmonary…
- Trial name
- DODS (NCT00720915)
- Testing
- Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 410 people
- Sponsor
- McMaster University
Deep Vein Thrombosis of Lower Limb, Lower Extremity Deep Venous Thrombosis Recurrent
Optimal Duration of Anticoagulation in Deep Venous Thrombosis
Prospective cohort study aimed at optimizing the duration of anticoagulant treatment in patients at their first episode of proximal deep venous thrombosis (DVT) of the lower extremities, whose pathogenesis is either unknown…
- Trial name
- MORGAGNI (NCT01285661)
- Testing
- Sodium warfarin
- Where
- Italy
- Volunteers
- 584 people
- Sponsor
- University of Padova
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Pulmonary Embolism
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be…
- Trial name
- NCT00182247
- Testing
- venogram
- Where
- 8 sites in Canada, Italy
- Volunteers
- 600 people
- Sponsor
- Hamilton Health Sciences Corporation
Rivaroxaban, Cancer-associated Thrombosis
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary…
- Conditions
- Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding
- Trial name
- NCT01989845
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Seoul National University Hospital
Venous Thromboembolism (VTE)
Identification of New Genetic Markers for the Risk of Recurrence of Venous Thromboembolism by Whole Genome Analysis
Venous thromboembolism (VTE) is a common and potentially fatal pathology in France. The risk of recurrence is around 5 to 7% per year.
- Trial name
- MARTHARecidive (NCT03977870)
- Testing
- vital status determination
- Where
- France
- Volunteers
- 843 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Atrial Fibrillation, Recurrent Venous Thromboembolism
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
- Trial name
- MACACOD (NCT04042155)
- Testing
- dabigatran, rivaroxaban, apixaban or edoxaban
- Where
- Spain
- Volunteers
- 1,600 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Venous Thromboembolism, Deep Venous Thrombosis
Aspirin for the Prevention of Recurrent Venous Thromboembolism
To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism, Atherosclerosis
- Trial name
- NCT00222677
- Testing
- aspirin
- Where
- 15 sites in Austria, Italy
- Volunteers
- 70 people
- Sponsor
- University Of Perugia
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer